Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington. more
Time Frame | KA | Sector | S&P500 |
---|
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 5.00M | 10.49M | 9.09M | 1.95M | 5.44M | [{"date":"2019-12-31","value":47.67,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":86.68,"profit":true},{"date":"2022-12-31","value":18.62,"profit":true},{"date":"2023-12-31","value":51.89,"profit":true}] |
Cost of Revenue | - | - | 669.00K | 734.00K | 9.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":91.14,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":1.23,"profit":true}] |
Gross Profit | 5.00M | 10.49M | 8.42M | 1.22M | 5.43M | [{"date":"2019-12-31","value":47.67,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":80.3,"profit":true},{"date":"2022-12-31","value":11.62,"profit":true},{"date":"2023-12-31","value":51.8,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 92.64% | 62.42% | 99.83% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":92.64,"profit":true},{"date":"2022-12-31","value":62.42,"profit":true},{"date":"2023-12-31","value":99.83,"profit":true}] |
Operating Expenses | 64.74M | 13.60M | 20.18M | 43.48M | 21.16M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":21.01,"profit":true},{"date":"2021-12-31","value":31.18,"profit":true},{"date":"2022-12-31","value":67.17,"profit":true},{"date":"2023-12-31","value":32.68,"profit":true}] |
Operating Income | (61.15M) | (3.12M) | (11.09M) | (41.53M) | (15.72M) | [{"date":"2019-12-31","value":-6115400000,"profit":false},{"date":"2020-12-31","value":-311500000,"profit":false},{"date":"2021-12-31","value":-1109300000,"profit":false},{"date":"2022-12-31","value":-4153100000,"profit":false},{"date":"2023-12-31","value":-1572300000,"profit":false}] |
Total Non-Operating Income/Expense | - | (8.96M) | (2.02M) | (25.66M) | (456.00K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-895700000,"profit":false},{"date":"2021-12-31","value":-201700000,"profit":false},{"date":"2022-12-31","value":-2565900000,"profit":false},{"date":"2023-12-31","value":-45600000,"profit":false}] |
Pre-Tax Income | (59.13M) | (7.11M) | (11.82M) | (63.45M) | (14.08M) | [{"date":"2019-12-31","value":-5912500000,"profit":false},{"date":"2020-12-31","value":-711200000,"profit":false},{"date":"2021-12-31","value":-1181700000,"profit":false},{"date":"2022-12-31","value":-6345300000,"profit":false},{"date":"2023-12-31","value":-1407600000,"profit":false}] |
Income Taxes | - | 6.76M | 143.00K | (386.00K) | 23.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.11,"profit":true},{"date":"2022-12-31","value":-5.71,"profit":false},{"date":"2023-12-31","value":0.34,"profit":true}] |
Income After Taxes | - | (13.88M) | (11.96M) | (63.07M) | (14.10M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1387700000,"profit":false},{"date":"2021-12-31","value":-1196000000,"profit":false},{"date":"2022-12-31","value":-6306700000,"profit":false},{"date":"2023-12-31","value":-1409900000,"profit":false}] |
Income From Continuous Operations | - | (7.11M) | (11.82M) | (63.45M) | (58.35M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-711200000,"profit":false},{"date":"2021-12-31","value":-1181700000,"profit":false},{"date":"2022-12-31","value":-6345300000,"profit":false},{"date":"2023-12-31","value":-5834900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (59.13M) | (13.88M) | (11.96M) | (63.07M) | (14.10M) | [{"date":"2019-12-31","value":-5912500000,"profit":false},{"date":"2020-12-31","value":-1387700000,"profit":false},{"date":"2021-12-31","value":-1196000000,"profit":false},{"date":"2022-12-31","value":-6306700000,"profit":false},{"date":"2023-12-31","value":-1409900000,"profit":false}] |
EPS (Diluted) | (161.00) | (38.08) | (26.95) | (24.35) | (1.50) | [{"date":"2019-12-31","value":-16100,"profit":false},{"date":"2020-12-31","value":-3808,"profit":false},{"date":"2021-12-31","value":-2695,"profit":false},{"date":"2022-12-31","value":-2435,"profit":false},{"date":"2023-12-31","value":-150,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
KA | |
---|---|
Cash Ratio | 0.10 |
Current Ratio | 0.14 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KA | |
---|---|
ROA (LTM) | -114.08% |
ROE (LTM) | -369.01% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 6.70 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -5.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.44 |
P/B | 9.65 |
Price/FCF | NM |
EV/R | 1.29 |
EV/Ebitda | NM |
Kineta Inc. (KA) share price today is $
Yes, Indians can buy shares of Kineta Inc. (KA) on Vested. To buy Kineta Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Kineta Inc. (KA) via the Vested app. You can start investing in Kineta Inc. (KA) with a minimum investment of $1.
You can invest in shares of Kineta Inc. (KA) via Vested in three simple steps:
The 52-week high price of Kineta Inc. (KA) is $2.95. The 52-week low price of Kineta Inc. (KA) is $0.33.
The price-to-earnings (P/E) ratio of Kineta Inc. (KA) is
The price-to-book (P/B) ratio of Kineta Inc. (KA) is 9.65
The dividend yield of Kineta Inc. (KA) is 0.00%
The market capitalization of Kineta Inc. (KA) is $7.05M
The stock symbol (or ticker) of Kineta Inc. is KA